Roivant Sciences Ltd.: Form 10-Q for the period ended Dec 31, 2023
Filed with the SEC on Feb 13, 2024 and accepted by EDGAR at Feb 13, 2024, 07:15 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-10-01 to 2023-12-31 | $37.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2023-04-01 to 2023-12-31 | $95.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2023-10-01 to 2023-12-31 | $123.7m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2023-04-01 to 2023-12-31 | $380.8m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2023-10-01 to 2023-12-31 | $197.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2023-04-01 to 2023-12-31 | $517.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-10-01 to 2023-12-31 | $5.06bn | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2023-04-01 to 2023-12-31 | $4.51bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-10-01 to 2023-12-31 | $9.4m | us-gaap:InterestExpense |
| Interest expense | 9 months2023-04-01 to 2023-12-31 | $27.6m | us-gaap:InterestExpense |
| Income tax | 3 months2023-10-01 to 2023-12-31 | $25.7m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2023-04-01 to 2023-12-31 | $31.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-10-01 to 2023-12-31 | $5.10bn | us-gaap:NetIncomeLoss |
| Net income | 9 months2023-04-01 to 2023-12-31 | $4.50bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-10-01 to 2023-12-31 | $6.03 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2023-04-01 to 2023-12-31 | $5.46 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-10-01 to 2023-12-31 | $6.37 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2023-04-01 to 2023-12-31 | $5.79 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-10-01 to 2023-12-31 | 844,461,685 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2023-04-01 to 2023-12-31 | 824,310,013 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2023-04-01 to 2023-12-31 | −$656.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2023-04-01 to 2023-12-31 | $1.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-12-31 | $6.67bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-12-31 | $6.81bn | us-gaap:AssetsCurrent |
| Total assets | At period end2023-12-31 | $7.31bn | us-gaap:Assets |
| Current liabilities | At period end2023-12-31 | $244.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-12-31 | $728.1m | us-gaap:Liabilities |
| Long-term debt | At period end2023-12-31 | $403.3m | us-gaap:LongTermDebt |
| Current portion of debt | At period end2023-12-31 | $45.7m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2023-12-31 | $6.09bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001140361-24-007260. Last ingested by Listed: Nov 5, 2026, 21:32 ET. Listed shows no prices and gives no investment advice.